{"DataElement":{"publicId":"5990047","version":"1","preferredName":"Exocrine Pancreatic Cancer AJCC Edition 8 Group Stage","preferredDefinition":"Stage group based on the combination of T, N, and M categories and relevant prognostic factors for exocrine pancreatic carcinoma, using AJCC Ed. 8 criteria.","longName":"EPAN_AJC8_DZ_STG","context":"NCI Standards","contextVersion":"1","DataElementConcept":{"publicId":"3452385","version":"1","preferredName":"Pancreas Neoplasm Stage Grouping","preferredDefinition":"A non-encapsulated elongated and lobulated organ, extending from the concavity of the duodenum to the spleen; it consists of a head, an elongated body, and a tail. It contains two functional components: an exocrine component that secretes juices into the intestine and an endocrine component that secretes hormones (insulin and glucagon)._A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias._An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage.","longName":"3452357v1.0:2230143v1.0","context":"NCI Standards","contextVersion":"1","ObjectClass":{"publicId":"3452357","version":"1","preferredName":"Pancreas Neoplasm","preferredDefinition":"A non-encapsulated elongated and lobulated organ, extending from the concavity of the duodenum to the spleen; it consists of a head, an elongated body, and a tail. It contains two functional components: an exocrine component that secretes juices into the intestine and an endocrine component that secretes hormones (insulin and glucagon).:A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","longName":"C12393:C3262","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pancreas","conceptCode":"C12393","definition":"An organ behind the lower part of the stomach that is the shape of a fish and about the size of a hand. It is a compound gland composed of both exocrine and endocrine tissues. The endocrine pancreas makes insulin so that the body can use glucose (sugar) for energy. The exocrine pancreas makes enzymes that help the body digest food. Spread all over the pancreas are areas called the Islets of Langerhans. The cells in these areas each have a special purpose. The alpha cells make glucagon, which raises the level of glucose in the blood; the beta cells make insulin; the delta cells make somatostatin. There are also PP cells and D1 cells, about which little is known.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm","conceptCode":"C3262","definition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BF79E0A4-6392-D3E2-E040-BB89AD4323E5","latestVersionIndicator":"Yes","beginDate":"2012-05-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-07","modifiedBy":"ONEDATA","dateModified":"2012-05-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2230143","version":"1","preferredName":"Stage Grouping","preferredDefinition":"Stage Grouping; an assessment based on the combined evaluation of the patient's T stage, M stage, and N stage. (caDSR)","longName":"C38027","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage Grouping","conceptCode":"C38027","definition":"An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F752037A-4CC2-36A8-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-05-18","modifiedBy":"ONEDATA","dateModified":"2005-05-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"BF79FA5D-4C3E-89D9-E040-BB89AD435E8F","latestVersionIndicator":"Yes","beginDate":"2012-05-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-07","modifiedBy":"TAYLORT","dateModified":"2017-09-13","changeDescription":"9/13/17 tt transferred context; changed Reg Status to Qualified. Created for CRF standard harmonization. Released per final community approval. mc 5/15/12","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6032060","version":"1","preferredName":"Exocrine Pancreatic Carcinoma American Joint Committee on Cancer Edition 8 Group Stage","preferredDefinition":"A term that refers to the staging of exocrine pancreatic cancer according to the American Joint Committee on Cancer, 8th edition. This staging system applies to pancreatic ductal adenocarcinoma, acinar cell carcinoma, intraductal papillary mucinous neoplasm with associated invasive carcinoma, intraductal tubulopapillary neoplasm with associated invasive carcinoma, colloid carcinoma, mucinous cystic neoplasm with associated invasive carcinoma, solid pseudopapillary neoplasm, large cell neuroendocrine carcinoma, small cell neuroendocrine carcinoma, and pancreatoblastoma. Well-differentiated neuroendocrine tumors are not staged using this staging system. (from AJCC 8th Ed.)._An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage._The extent of a cancer in the body. Staging is usually based on the size of the tumor, whether lymph nodes contain cancer, and whether the cancer has spread from the original site to other parts of the body.","longName":"6032060v1.0","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"lV","valueDescription":"Stage IV Pancreatic Cancer AJCC v8","ValueMeaning":{"publicId":"6032062","version":"1","preferredName":"Stage IV Pancreatic Cancer AJCC v8","longName":"6032062","preferredDefinition":"Stage IV includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IV Pancreatic Cancer AJCC v8","conceptCode":"C134930","definition":"Stage IV includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E909306-BC91-4055-E053-F662850AFE76","latestVersionIndicator":"Yes","beginDate":"2017-11-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5E909306-BCAA-4055-E053-F662850AFE76","beginDate":"2017-11-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-22","modifiedBy":"ONEDATA","dateModified":"2017-11-22","deletedIndicator":"No"},{"value":"lll","valueDescription":"Stage III Pancreatic Cancer AJCC v8","ValueMeaning":{"publicId":"6032064","version":"1","preferredName":"Stage III Pancreatic Cancer AJCC v8","longName":"6032064","preferredDefinition":"Stage III includes: (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4, Any N, M0). T1: Tumor measuring 2 cm or less in greatest dimension. T2: Tumor measuring more than 2 cm and 4 cm or less in greatest dimension. T3: Tumor measuring more than 4 cm in greatest dimension. T4: Tumor involving the celiac axis, superior mesenteric artery, and/or common hepatic artery, regardless of size. N2: Metastasis in four or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage III Pancreatic Cancer AJCC v8","conceptCode":"C134928","definition":"Stage III includes: (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4, Any N, M0). T1: Tumor measuring 2 cm or less in greatest dimension. T2: Tumor measuring more than 2 cm and 4 cm or less in greatest dimension. T3: Tumor measuring more than 4 cm in greatest dimension. T4: Tumor involving the celiac axis, superior mesenteric artery, and/or common hepatic artery, regardless of size. N2: Metastasis in four or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E909306-BCB7-4055-E053-F662850AFE76","latestVersionIndicator":"Yes","beginDate":"2017-11-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5E909306-BCD0-4055-E053-F662850AFE76","beginDate":"2017-11-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-22","modifiedBy":"ONEDATA","dateModified":"2017-11-22","deletedIndicator":"No"},{"value":"llB","valueDescription":"Stage IIB Pancreatic Cancer AJCC v8","ValueMeaning":{"publicId":"6032066","version":"1","preferredName":"Stage IIB Pancreatic Cancer AJCC v8","longName":"6032066","preferredDefinition":"Stage IIB includes: (T1, N1, M0); (T2, N1, M0); (T3, N1, M0). T1: Tumor measuring 2 cm or less in greatest dimension. T2: Tumor measuring more than 2 cm and 4 cm or less in greatest dimension. T3: Tumor measuring more than 4 cm in greatest dimension. N1: Metastasis in one to three regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IIB Pancreatic Cancer AJCC v8","conceptCode":"C134927","definition":"Stage IIB includes: (T1, N1, M0); (T2, N1, M0); (T3, N1, M0). T1: Tumor measuring 2 cm or less in greatest dimension. T2: Tumor measuring more than 2 cm and 4 cm or less in greatest dimension. T3: Tumor measuring more than 4 cm in greatest dimension. N1: Metastasis in one to three regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E909306-BCDD-4055-E053-F662850AFE76","latestVersionIndicator":"Yes","beginDate":"2017-11-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5E909306-BCF6-4055-E053-F662850AFE76","beginDate":"2017-11-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-22","modifiedBy":"ONEDATA","dateModified":"2017-11-22","deletedIndicator":"No"},{"value":"llA","valueDescription":"Stage IIA Pancreatic Cancer AJCC v8","ValueMeaning":{"publicId":"6032068","version":"1","preferredName":"Stage IIA Pancreatic Cancer AJCC v8","longName":"6032068","preferredDefinition":"Stage IIA includes: T3, N0, M0. T3: Tumor measuring more than 4 cm in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IIA Pancreatic Cancer AJCC v8","conceptCode":"C134925","definition":"Stage IIA includes: T3, N0, M0. T3: Tumor measuring more than 4 cm in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E909306-BD03-4055-E053-F662850AFE76","latestVersionIndicator":"Yes","beginDate":"2017-11-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5E909306-BD1C-4055-E053-F662850AFE76","beginDate":"2017-11-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-22","modifiedBy":"ONEDATA","dateModified":"2017-11-22","deletedIndicator":"No"},{"value":"lB","valueDescription":"Stage IB Pancreatic Cancer AJCC v8","ValueMeaning":{"publicId":"6032072","version":"1","preferredName":"Stage IB Pancreatic Cancer AJCC v8","longName":"6032072","preferredDefinition":"Stage IB includes: T2, N0, M0. T2: Tumor measuring more than 2 cm and 4 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IB Pancreatic Cancer AJCC v8","conceptCode":"C134920","definition":"Stage IB includes: T2, N0, M0. T2: Tumor measuring more than 2 cm and 4 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E909306-BD4F-4055-E053-F662850AFE76","latestVersionIndicator":"Yes","beginDate":"2017-11-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5E909306-BD68-4055-E053-F662850AFE76","beginDate":"2017-11-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-22","modifiedBy":"ONEDATA","dateModified":"2017-11-22","deletedIndicator":"No"},{"value":"lA","valueDescription":"Stage IA Pancreatic Cancer AJCC v8","ValueMeaning":{"publicId":"6032074","version":"1","preferredName":"Stage IA Pancreatic Cancer AJCC v8","longName":"6032074","preferredDefinition":"Stage IA includes: T1, N0, M0. T1: Tumor measuring 2 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IA Pancreatic Cancer AJCC v8","conceptCode":"C134917","definition":"Stage IA includes: T1, N0, M0. T1: Tumor measuring 2 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E909306-BD75-4055-E053-F662850AFE76","latestVersionIndicator":"Yes","beginDate":"2017-11-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5E909306-BD8E-4055-E053-F662850AFE76","beginDate":"2017-11-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-22","modifiedBy":"ONEDATA","dateModified":"2017-11-22","deletedIndicator":"No"},{"value":"0","valueDescription":"Stage 0 Pancreatic Cancer AJCC v8","ValueMeaning":{"publicId":"6032078","version":"1","preferredName":"Stage 0 Pancreatic Cancer AJCC v8","longName":"6032078","preferredDefinition":"Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ. This includes high-grade pancreatic intraepithelial neoplasia (PanIn-3), intraductal papillary mucinous neoplasm with high-grade dysplasia, intraductal tubulopapillary neoplasm with high-grade dysplasia, and mucinous cystic neoplasm with high-grade dysplasia.  N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage 0 Pancreatic Cancer AJCC v8","conceptCode":"C134914","definition":"Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ. This includes high-grade pancreatic intraepithelial neoplasia (PanIn-3), intraductal papillary mucinous neoplasm with high-grade dysplasia, intraductal tubulopapillary neoplasm with high-grade dysplasia, and mucinous cystic neoplasm with high-grade dysplasia.  N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E909306-BDC1-4055-E053-F662850AFE76","latestVersionIndicator":"Yes","beginDate":"2017-11-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5E909306-BDDA-4055-E053-F662850AFE76","beginDate":"2017-11-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-22","modifiedBy":"ONEDATA","dateModified":"2017-11-22","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6679310","version":"1","preferredName":"Pancreatic Cancer by AJCC v8 Stage Stage Grouping Stage","preferredDefinition":"A term that refers to the staging of exocrine pancreatic cancer according to the American Joint Committee on Cancer, 8th edition. This staging system applies to pancreatic ductal adenocarcinoma, acinar cell carcinoma, intraductal papillary mucinous neoplasm with associated invasive carcinoma, intraductal tubulopapillary neoplasm with associated invasive carcinoma, colloid carcinoma, mucinous cystic neoplasm with associated invasive carcinoma, solid pseudopapillary neoplasm, large cell neuroendocrine carcinoma, small cell neuroendocrine carcinoma, and pancreatoblastoma. Well-differentiated neuroendocrine tumors are not staged using this staging system. (from AJCC 8th Ed.):An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.:The extent of a cancer in the body. Staging is usually based on the size of the tumor, whether lymph nodes contain cancer, and whether the cancer has spread from the original site to other parts of the body.","longName":"C134909:C38027:C16899","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pancreatic Cancer by AJCC v8 Stage","conceptCode":"C134909","definition":"A term that refers to the staging of exocrine pancreatic cancer according to the American Joint Committee on Cancer, 8th edition. This staging system applies to pancreatic ductal adenocarcinoma, acinar cell carcinoma, intraductal papillary mucinous neoplasm with associated invasive carcinoma, intraductal tubulopapillary neoplasm with associated invasive carcinoma, colloid carcinoma, mucinous cystic neoplasm with associated invasive carcinoma, solid pseudopapillary neoplasm, large cell neuroendocrine carcinoma, small cell neuroendocrine carcinoma, and pancreatoblastoma. Well-differentiated neuroendocrine tumors are not staged using this staging system. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Stage Grouping","conceptCode":"C38027","definition":"An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm Stage","conceptCode":"C16899","definition":"The extent of a cancer in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"849A5588-2C23-1DF5-E053-F662850A6181","latestVersionIndicator":"Yes","beginDate":"2019-03-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-21","modifiedBy":"ONEDATA","dateModified":"2019-03-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"5E909306-BC6B-4055-E053-F662850AFE76","latestVersionIndicator":"Yes","beginDate":"2017-11-22","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-22","modifiedBy":"TAYLORT","dateModified":"2019-05-03","changeDescription":"5-3-19 released; tmt. 3/21/19 Edits per ed. 8; tmt. 11/22/17 tt created for standardization, associated with CS/CSI; supercedes VD 3452475.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"5506114","version":"1","longName":"Pancreas","context":"MCL","ClassificationSchemeItems":[{"publicId":"5854655","version":"1","longName":"Pancreas Core","context":"MCL"},{"publicId":"7781144","version":"1","longName":"Pancreas PCA Pilot","context":"MCL"}]},{"publicId":"5574838","version":"1","longName":"Staging/Extent of Disease","context":"NCI Standards","ClassificationSchemeItems":[{"publicId":"6005920","version":"1","longName":"AJCC Edition 8","context":"NCI Standards"},{"publicId":"10000091","version":"1","longName":"Pancreatic","context":"NCI Standards"}]},{"publicId":"6437797","version":"1","longName":"Pre-Cancer Atlas Pilot","context":"MCL","ClassificationSchemeItems":[{"publicId":"7001793","version":"1","longName":"Pancreas PCA Pilot","context":"MCL"}]}],"AlternateNames":[{"name":"MCL","type":"USED_BY","context":"MCL"},{"name":"exocrine_group_stage_AJCC_8","type":"MCL Alt Name","context":"NCI Standards"}],"ReferenceDocuments":[{"name":"Disease stage","type":"Preferred Question Text","description":"Disease stage","url":null,"context":"NCI Standards"},{"name":"MCL-PCA-1","type":"Alternate Question Text","description":"Exocrine Group Stage","url":null,"context":"MCL"},{"name":"MCL-Template Name","type":"Data Collection Template","description":"pancreas_v0-1_template-1.xlsx","url":"https://mcl.nci.nih.gov/resources/standards/mcl-cdes","context":"MCL"}],"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"5AE54B8E-0F67-0249-E053-F662850A91F1","latestVersionIndicator":"Yes","beginDate":"2017-10-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-10-06","modifiedBy":"COLBERTM","dateModified":"2021-09-16","changeDescription":"8/17/21 mr Added Alt Name and Ref Doc to match MCL DD. 5-3-19 released; tmt. 3/21/19 Updates per ed. 8; tmt.  11/22/17 tt associated with VD and CS/CSI. 10/6/17 tt Created for standard harmonization. Incomplete pending updates to VD per NCIt Ed 8 caDSR concept loading; supercedes CDE 3452507.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}